CAR-T Cell Therapy Market Size Worth $118,680.68 Million By 2032 | CAGR: 43.20%

The global CAR-T cell therapy market size is expected to reach USD 118,680.68 million by 2032, according to a new study by Polaris Market Research. The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report, By Target Antigen (CD19/CD22, BCMA, and Others); By Indication; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The CAR-T cell therapy market is experiencing significant growth as it utilizes the immune system to combat cancer. This groundbreaking approach involves modifying a patient's own T cells, a type of white blood cell, to express chimeric antigen receptors (CARs) on their surface. These CARs enable the T cells to recognize and target specific antigens in cancer cells, leading to their destruction. CAR-T therapy has shown promising results in treating specific blood malignancies and is being explored for its potential in other types of cancer.

In CAR-T treatment, T cells from the patient's blood are taken out and genetically modified in a lab to produce receptors that bind to proteins prevalent in cancer cells. Large quantities of these modified CAR-T cells are then produced and administered to the patient. By enhancing the T cells' ability to locate and attack cancer cells, CAR-T therapy has the potential to revolutionize cancer treatment.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample

However, the COVID-19 pandemic has impacted the CAR-T cell therapy market. Lockdowns and disruptions in the supply chain have resulted in delays and interruptions in the production and availability of raw materials needed for CAR-T cell manufacturing. This has created challenges for life science and biopharma companies, causing them to wait for new raw materials for CAR-T cell production. Efforts are underway to address these supply chain issues and ensure a steady supply of materials to support the manufacturing of CAR-T cells during these challenging times.

CAR-T Cell Therapy Market Report Highlights

• CD19/CD22 is the CAR-T cell therapy with the largest market share. It has shown remarkable clinical results in leukemia and lymphoma treatment, gaining regulatory approval and proving effective in achieving patient remission.
• DLBCL (Diffuse Large B-cell Lymphoma) is a prominent indication in the CAR-T cell therapy market, holding a significant market share. This fast-growing cancer of B-cell origin is a prevalent form of non-Hodgkin lymphoma affecting the lymphatic system.
• North America is set to lead the market, driven by rising cancer incidence and the growing biotechnology industry. The region's demand for cancer treatments is increasing accordingly.
• The global key market players include Amgen Inc. (US), Bellicum Pharmaceuticals, Inc. (US), Bluebird Bio (US), Caribou Biosciences, Inc. (US), Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc., Intellia Therapeutics, Johnson & Johnson, Merck KGaA, Nanjing Legend Biotechnology Co., Ltd., Noile-Immune Biotech, Novartis International AG, Pfizer Inc., Sangamo Therapeutics, Inc., Servier Laboratories.

Polaris Market Research has segmented the CAR-T Cell Therapy market report based on target antigen, indication, and region:

CAR-T Cell Therapy, Target Antigen Outlook (Revenue - USD Million, 2019 - 2032)

• CD19/CD22
• BCMA (B-Cell Maturation Antigen)
• Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)

CAR-T Cell Therapy, Indication Outlook (Revenue - USD Million, 2019 - 2032)

• DLBCL
• ALL
• CLL
• MM
• FL
• Mastozytosis
• Myeloid Fibrosis
• MLL
• Thymic Cancer
• Glioblastoma
• AML
• Others

CAR-T Cell Therapy, Regional Outlook (Revenue - USD Million, 2019 - 2032)

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Austria
• Rest of Europe

• Asia Pacific

• China
• India
• Japan
• South Korea
• Australia
• Rest of Asia Pacific

• Latin America

• Brazil
• Mexico
• Rest of Latin America

• Middle East & Africa

• UAE
• Saudi Arabia
• Rest of Middle East & Africa